

LIST OF FIGURES

CHAPTER 1

- 1.1 Schematic representation of the blood coagulation cascade
- 1.2 Schematic representation of a fibrinogen molecule and a fibrin monomer
- 1.3 King cobra habitat in the south-east Asian countries

CHAPTER 2

- 2.1 protein banding pattern of king cobra venom under non reduced condition with molecular weight markers
- 2.2 Indirect Hemolytic activity of *O. hannah* venom with increasing concentrations
- 2.3 Recalcification time of citrated human plasma with increasing concentrations of *O. hannah* venom initiated by CaCl₂
- 2.4 Hyaluronan Zymogram showing hyaluronidase activity band of king cobra venom under non-reduced condition
- 2.5 Fibrinogenolytic activity of *O. hannah* venom on purified human fibrinogen whose degradative products are run on a 10% SDS-PAGE under reduced condition
- 2.6 Fibrinolytic activity of *O. hannah* venom by plate method showing increasing activity zones along with increasing concentration with activity zone of urokinase (U) taken as positive control on agarose gel
- 2.7 Effect of *O. hannah* venom on collagen induced human platelet aggregation

CHAPTER 3

- 3.1 SDS-PAGE pattern of venoms of *O. hannah*, *D. russellii*, *E. carinatus* and *N. naja* venoms under non-reduced condition along with molecular weight markers

- 3.2A Effect of three venoms on plasma recalcification time of citrated human plasma
- 3.2B Effect of *E. carinatus* venom in increasing concentration on clotting time of citrated human plasma in the absence of CaCl₂
- 3.3 Dose dependent effect of four venoms on the (A) activated partial thromboplastin time ratio, (B) pro-thrombin time for three venoms (*D. russellii*, *N. naja* and *O. hannah*) and (C) thrombin clotting time for four venoms (*D. russellii*, *E. carinatus*, *N. naja* and *O. hannah*)
- 3.4 Fibrinogenolytic activity of four venoms on purified human fibrinogen and the degradative products separated on a 10% SDS-PAGE under reduced condition along with molecular weight markers
- 3.5 Fibrinolytic activity of snake venoms on the washed whole blood clot (A) and plasma clot (B) estimated quantitatively by colorimetric method
- 3.6 Effect of four venoms on washed plasma clot whose degradative products were analyzed on a 10% SDS-PAGE under reduced condition along with molecular weight markers
- 3.7 Inhibitory activities of three venoms on platelet aggregation induced by ADP, Epinephrine and thrombin, recorded using a dual channel *Chrono-log* model 700-2 aggregometer

CHAPTER 4

- 4.1 Fig. 4.1: Elution profile of anti-*O. hannah* sera in Protein-A sepharose CL-6B affinity column (A) and SDS-PAGE banding pattern of anti- *O. hannah* sera isolated anti-*O. hannah* IgG antibodies under non-reducing condition.
- 4.2 Cross-reactivity of four snake venoms with antivenoms: BSV (A), VB (B) and OH-IgG (C) in Ouchterlony immuno double diffusion assay
- 4.3 Cross-reactivity of three snake venoms with antivenoms from BSV (A), VB (B), and OH-IgG (C) in ELISA

- 4.4 SDS-PAGE banding pattern and Western blots showing reactivity of antivenoms BSV (B), VB (C) and OH-IgG (D) with four Snake venoms resolved on a 10% SDS-PAGE
- 4.5 Inhibition of enzyme activities of *O. hannah* venom: (A) Protease, (B) Hyaluronidase and (C) Phospholipase activities
- 4.6 Inhibition of pro-coagulant activity of *O. hannah* venom when incubated with increasing amounts (w/w) of BSV, VB and OH-IgG antivenoms
- 4.7 Inhibition of myotoxicity of *O. hannah* venom when pre-incubated with increasing amounts (w/w) of BSV, VB and OH-IgG antivenoms, estimated by the levels of Creatine phosphokinase (A) and Lactate dehydrogenase (B) activities
- 4.8 Inhibition of edema inducing activity: *O. hannah* venom pre-incubated with increasing amounts (w/w) of BSV, VB & OH-IgG antivenoms

CHAPTER 5

- 5.1 Elution profile of king cobra venom in Sephadex G-100 column chromatography
- 5.2 Elution profile of CM-Sephadex C 25 column chromatography for peak V of king cobra venom obtained from Sephadex G-100 column chromatography
- 5.3 protein band pattern of king cobra venom, isolated protease and casein zymography of the protease resolved on 10% SDS-PAGE under non-reduced condition along with molecular weight markers
- 5.4 Effect of protease on recalcification time of citrated human plasma
- 5.5 Dose dependent (A) and time dependent (B) Fibrinogenolytic activity of protease, the degradation products resolved on 10% SDS-PAGE under reduced condition.
- 5.6A Effect of increasing concentration of β -fibrinogenase on ADP induced platelet

aggregation

- 5.6B Effect of increasing concentration of β -fibrinogenase on epinephrine induced platelet aggregation
- 5.6C Effect of increasing concentration of β -fibrinogenase on thrombin induced platelet aggregation